

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/MA6DBF935F31EN.html>

Date: October 2022

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: MA6DBF935F31EN

Abstracts

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2022'; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.

The report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2022' outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and

molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Anxiety Disorders, Depression, Alzheimer's Disease, Blepharospasm, Fragile X Syndrome, Major Depressive Disorder, Pain, Parkinson's Disease, Schizophrenia, Substance (Drug) Abuse, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Cognitive Impairment, Dementia, DiGeorge Syndrome, Drug Addiction, Dyskinesia, Dystonia, Seizures, Spasmodic Torticollis (Cervical Dystonia), Stammering (Stuttering), Trigeminal Neuralgia (Tic Douloureux) and Unspecified.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies
Involved in Therapeutics Development

Addex Therapeutics Ltd

Allyx Therapeutics Inc

Appello Pharmaceuticals Inc

Bristol-Myers Squibb Co

Hua Medicine Shanghai Ltd

Laboratorio Farmaceutico CT Srl

Lactocore Inc

Nobias Therapeutics Inc

Noema Pharma AG

Novartis AG

Park of Active Molecules

Tempero Bio

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
alloswitch-1 - Drug Profile

Product Description

Mechanism Of Action

ALX-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AP-612 - Drug Profile

Product Description

Mechanism Of Action

basimglurant - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-952048 - Drug Profile

Product Description

Mechanism Of Action

dipraglurant - Drug Profile

Product Description

Mechanism Of Action

History of Events

dipraglurant ER - Drug Profile

Product Description

Mechanism Of Action

dipraglurant IR - Drug Profile

Product Description

Mechanism Of Action

History of Events

GET-73 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HTL-0014242 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LCGM-10 - Drug Profile

Product Description

Mechanism Of Action

mavoglurant - Drug Profile

Product Description

Mechanism Of Action

History of Events

mGLUR5 NAM - Drug Profile

Product Description

Mechanism Of Action

NB-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PAM-12 - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

VU-0092273 - Drug Profile

Product Description

Mechanism Of Action

VU-0431316 - Drug Profile

Product Description

Mechanism Of Action

VU-0467558 - Drug Profile

Product Description

Mechanism Of Action

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones

Featured News & Press Releases

Sep 06, 2022: Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation study

Jun 17, 2022: Addex terminates dipraglurant phase 2b/3 study in patients with dyskinesia associated with Parkinson's disease due to slow recruitment rate

May 27, 2022: Addex provides update on dipraglurant blepharospasm phase 2 feasibility clinical study

Apr 13, 2022: Addex Therapeutics completes patient enrollment for dipraglurant blepharospasm phase 2 clinical study

Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Feb 14, 2022: Noema Pharma announces FDA Investigational New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in

blepharospasm

Jul 07, 2021: Noema Pharma to host a key opinion leader webinar on seizures in tuberous sclerosis complex

Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson's Disease

May 17, 2021: Addex's Dipraglurant restores synaptic plasticity in models of Dystonia

Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results

Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome

Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders

Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share

Feb 06, 2017: Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Allyx Therapeutics Inc, 2022
Pipeline by Appello Pharmaceuticals Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Hua Medicine Shanghai Ltd, 2022
Pipeline by Laboratorio Farmaceutico CT Srl, 2022
Pipeline by Lactocore Inc, 2022
Pipeline by Nobias Therapeutics Inc, 2022
Pipeline by Noema Pharma AG, 2022
Pipeline by Novartis AG, 2022
Pipeline by Park of Active Molecules, 2022
Pipeline by Tempero Bio, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/MA6DBF935F31EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA6DBF935F31EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970